Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 배상철 | - |
dc.date.accessioned | 2018-10-10T07:08:00Z | - |
dc.date.available | 2018-10-10T07:08:00Z | - |
dc.date.issued | 2016-08 | - |
dc.identifier.citation | ARTHRITIS & RHEUMATOLOGY, v. 68, NO. 8, Page. 1932-1944 | en_US |
dc.identifier.issn | 2326-5191 | - |
dc.identifier.issn | 2326-5205 | - |
dc.identifier.uri | https://onlinelibrary.wiley.com/doi/abs/10.1002/art.39674 | - |
dc.identifier.uri | https://repository.hanyang.ac.kr/handle/20.500.11754/76413 | - |
dc.description.abstract | Objective. To study bidirectional change and predictors of change in estimated glomerular filtration rate (GFR) and proteinuria in lupus nephritis (LN) using a multistate modeling approach. Methods. Patients in the Systemic Lupus International Collaborating Clinics inception cohort were classified annually into estimated GFR state 1 (>60 ml/minute), state 2 (30-60 ml/minute), or state 3 (<30 ml/minute) and estimated proteinuria state 1 (<0.25 gm/day), state 2 (0.25-3.0 gm/day), or state 3 (>3.0 gm/day), or end-stage renal disease (ESRD) or death. Using multistate modeling, relative transition rates between states indicated improvement and deterioration. Results. Of 1,826 lupus patients, 700 (38.3%) developed LN. During a mean +/- SD follow-up of 5.2 +/- 3.5 years, the likelihood of improvement in estimated GFR and estimated proteinuria was greater than the likelihood of deterioration. After 5 years, 62% of patients initially in estimated GFR state 3 and 11% of patients initially in estimated proteinuria state 3 transitioned to ESRD. The probability of remaining in the initial states 1, 2, and 3 was 85%, 11%, and 3%, respectively, for estimated GFR and 62%, 29%, and 4%, respectively, for estimated proteinuria. Male sex predicted improvement in estimated GFR states; older age, race/ethnicity, higher estimated proteinuria state, and higher renal biopsy chronicity scores predicted deterioration. For estimated proteinuria, race/ethnicity, earlier calendar years, damage scores without renal variables, and higher renal biopsy chronicity scores predicted deterioration; male sex, presence of lupus anticoagulant, class V nephritis, and mycophenolic acid use predicted less improvement. Conclusion. In LN, the expected improvement or deterioration in renal outcomes can be estimated by multistate modeling and is preceded by identifiable risk factors. New therapeutic interventions for LN should meet or exceed these expectations. | en_US |
dc.description.sponsorship | The Systemic Lupus International Collaborating Clinics (SLICC) research network received funding for this study from Bristol-Myers Squibb. The Hopkins Lupus Cohort is supported by the NIH (grant AR43727). The Montreal General Hospital Lupus Clinic is partially supported by the Singer Family Fund for Lupus Research. Dr. Hanly's work was supported by the Canadian Institutes of Health (research grant MOP-86526). Dr. Bae's work was supported by the Korea Healthcare Technology R&D Project, Ministry for Health and Welfare, Republic of Korea (grant A120404). Dr. Gordon's work was supported by Lupus UK, Sandwell and West Birmingham Hospitals NHS Trust, and the NIHR/Wellcome Trust Clinical Research Facility in Birmingham. Dr. Clarke holds The Arthritis Society Chair in Rheumatic Diseases at the University of Calgary. Drs. Isenberg and Rahman's work was supported by the NIHR University College London Hospitals Biomedical Research Centre. Dr. Fortin holds a Tier 1 Canada Research Chair on Systemic Autoimmune Rheumatic Diseases at Universite Laval, and part of this work was done while he was a Distinguished Senior Investigator of The Arthritis Society. Dr. Bruce is an NIHR Senior Investigator and his work was supported by Arthritis Research UK, the National Institute for Health Research Manchester Biomedical Research Unit, and the NIHR/Wellcome Trust Manchester Clinical Research Facility. Dr. Jacobsen's work was supported by the Danish Rheumatism Association (A1028) and the Novo Nordisk Foundation (A05990). Dr. Ramsey-Goldman's work was supported by the NIH (grants 8UL1TR000150 [formerly UL-1RR-025741], K24-AR-02318, and P60AR064464 [formerly P60-AR-48098]). Dr. Dooley's work was supported by the NIH (grant RR00046). Dr. Ruiz-Irastorza's work was supported by the Department of Education, Universities and Research of the Basque Government and the Basque Biobank. Drs. Su and Farewell's work was supported by the MRC (UK) (U105261167). Dr. Clarke has received consulting fees, speaking fees, and/or honoraria from Eli Lilly and MedImmune/AstraZeneca (less than $10,000 each). Dr. Bruce has received consulting fees, speaking fees, and/or honoraria from Eli Lilly, UCB, Roche, Merck Serono, MedImmune (less than $10,000 each) and grants from UCB, Genzyme Sanofi, and GlaxoSmithKline. Dr. Fortin has received consulting fees, speaking fees, and/or honoraria from Eli Lilly, AbbVie, and GlaxoSmithKline (less than $10,000 each). Dr. Manzi has received grants from UCB and Human Genome Sciences/GlaxoSmithKline and has received consulting fees from Exagen Diagnostics, GlaxoSmithKline, Eli Lilly, and UBC (less than $10,000 each). Dr. Kalunian has received grants from UCB, Human Genome Sciences/GlaxoSmithKline, Takeda, Ablynx, Bristol-Myers Squibb, Pfizer, and Kyowa Hakko Kirin, and has received consulting fees from Exagen Diagnostics, Genentech, Eli Lilly, Bristol-Myers Squibb, and Anthera (less than $10,000 each). | en_US |
dc.language.iso | en | en_US |
dc.publisher | WILEY-BLACKWELL | en_US |
dc.subject | ANTIPHOSPHOLIPID ANTIBODIES | en_US |
dc.subject | NEUROPSYCHIATRIC EVENTS | en_US |
dc.subject | REVISED CRITERIA | en_US |
dc.subject | RENAL SURVIVAL | en_US |
dc.subject | PROTEIN-S | en_US |
dc.subject | ERYTHEMATOSUS | en_US |
dc.subject | DISEASE | en_US |
dc.subject | RISK | en_US |
dc.subject | CLASSIFICATION | en_US |
dc.subject | PREVALENCE | en_US |
dc.title | A Longitudinal Analysis of Outcomes of Lupus Nephritis in an International Inception Cohort Using a Multistate Model Approach | en_US |
dc.type | Article | en_US |
dc.relation.no | 8 | - |
dc.relation.volume | 68 | - |
dc.identifier.doi | 10.1002/art.39674 | - |
dc.relation.page | 1932-1944 | - |
dc.relation.journal | ARTHRITIS & RHEUMATOLOGY | - |
dc.contributor.googleauthor | Hanly, John G. | - |
dc.contributor.googleauthor | Su, Li | - |
dc.contributor.googleauthor | Urowitz, Murray B. | - |
dc.contributor.googleauthor | Romero-Diaz, Juanita | - |
dc.contributor.googleauthor | Gordon, Caroline | - |
dc.contributor.googleauthor | Bae, Sang-Cheol | - |
dc.contributor.googleauthor | Bernatsky, Sasha | - |
dc.contributor.googleauthor | Clarke, Ann E. | - |
dc.contributor.googleauthor | Wallace, Daniel J. | - |
dc.contributor.googleauthor | Merrill, Joan T. | - |
dc.relation.code | 2016000467 | - |
dc.sector.campus | S | - |
dc.sector.daehak | COLLEGE OF MEDICINE[S] | - |
dc.sector.department | DEPARTMENT OF MEDICINE | - |
dc.identifier.pid | scbae | - |
dc.identifier.orcid | http://orcid.org/0000-0003-4658-1093 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.